Niacin (extended-release tablet): Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
|authorTag={{AP}}
|genericName=Nicotinic acid
|drugClass=[[Antihyperlipidemic Nicotinic Acid (class) Nutriceutical Nutritive Agent Vitamin B (class)
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Niacin in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Niacin in adult patients.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Niacin in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Niacin in pediatric patients.
|alcohol=Alcohol-Niacin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
}}
{{Chembox new
{{Chembox new
|ImageFile=Niacin structure svg.png
|ImageFile=Niacin structure svg.png

Revision as of 17:45, 6 February 2015

{{DrugProjectFormSinglePage |authorTag=Alberto Plate [4] |genericName=Nicotinic acid |drugClass=[[Antihyperlipidemic Nicotinic Acid (class) Nutriceutical Nutritive Agent Vitamin B (class) |blackBoxWarningTitle=TITLE |blackBoxWarningBody=Condition Name: (Content) |offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Niacin in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Niacin in adult patients. |offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Niacin in pediatric patients. |offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Niacin in pediatric patients. |alcohol=Alcohol-Niacin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. }} Template:Chembox new

WikiDoc Resources for Niacin (extended-release tablet)

Articles

Most recent articles on Niacin (extended-release tablet)

Most cited articles on Niacin (extended-release tablet)

Review articles on Niacin (extended-release tablet)

Articles on Niacin (extended-release tablet) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Niacin (extended-release tablet)

Images of Niacin (extended-release tablet)

Photos of Niacin (extended-release tablet)

Podcasts & MP3s on Niacin (extended-release tablet)

Videos on Niacin (extended-release tablet)

Evidence Based Medicine

Cochrane Collaboration on Niacin (extended-release tablet)

Bandolier on Niacin (extended-release tablet)

TRIP on Niacin (extended-release tablet)

Clinical Trials

Ongoing Trials on Niacin (extended-release tablet) at Clinical Trials.gov

Trial results on Niacin (extended-release tablet)

Clinical Trials on Niacin (extended-release tablet) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Niacin (extended-release tablet)

NICE Guidance on Niacin (extended-release tablet)

NHS PRODIGY Guidance

FDA on Niacin (extended-release tablet)

CDC on Niacin (extended-release tablet)

Books

Books on Niacin (extended-release tablet)

News

Niacin (extended-release tablet) in the news

Be alerted to news on Niacin (extended-release tablet)

News trends on Niacin (extended-release tablet)

Commentary

Blogs on Niacin (extended-release tablet)

Definitions

Definitions of Niacin (extended-release tablet)

Patient Resources / Community

Patient resources on Niacin (extended-release tablet)

Discussion groups on Niacin (extended-release tablet)

Patient Handouts on Niacin (extended-release tablet)

Directions to Hospitals Treating Niacin (extended-release tablet)

Risk calculators and risk factors for Niacin (extended-release tablet)

Healthcare Provider Resources

Symptoms of Niacin (extended-release tablet)

Causes & Risk Factors for Niacin (extended-release tablet)

Diagnostic studies for Niacin (extended-release tablet)

Treatment of Niacin (extended-release tablet)

Continuing Medical Education (CME)

CME Programs on Niacin (extended-release tablet)

International

Niacin (extended-release tablet) en Espanol

Niacin (extended-release tablet) en Francais

Business

Niacin (extended-release tablet) in the Marketplace

Patents on Niacin (extended-release tablet)

Experimental / Informatics

List of terms related to Niacin (extended-release tablet)

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [5]

Overview

Niacin, also known as nicotinic acid or vitamin B3, is a water-soluble vitamin discovered by Conrad Elvehjem in 1937. Its derivatives, NADH, NAD, NAD+, and NADP play essential roles in energy metabolism in the living cell and DNA repair (an enzymatic process in a living cell). [1] The designation vitamin B3 also includes the corresponding amide nicotinamide (or "niacinamide"), whose chemical formula is C6H6N2O.

Other functions of niacin include removing toxic chemicals from the body,[2] and assisting in the production of steroid hormones made by the adrenal gland, such as sex hormones and stress-related hormones.

History

Niacin was first discovered from the oxidation of nicotine to form nicotinic acid. When the properties of nicotinic acid were discovered, it was thought prudent to choose a name to dissociate it from nicotine, in order to avoid the perception that vitamins or niacin-rich food contains nicotine. The resulting name 'niacin' was derived from nicotinic acid + vitamin.

Niacin is also referred to as Vitamin B3 because it was the third of the B vitamins to be discovered. It has historically been referred to as "vitamin PP", a name derived from the term "pellagra-preventing factor".

Dietary needs

The recommended daily allowance of niacin is 2-12 mg a day for children, 14 mg a day for women, 16 mg a day for men, and 18 mg a day for pregnant or breast-feeding women.[3]

Severe deficiency of niacin in the diet causes the disease pellagra, whereas mild deficiency slows down the metabolism, causing decreased tolerance to cold.

Dietary niacin deficiency tends to occur only in areas where people eat corn (maize), the only grain low in niacin, as a staple food, and that do not use lime during meal/flour production. Alkali lime releases the tryptophan from the corn in a process called nixtamalization so that it can be absorbed in the intestine, and converted to niacin.[2]

Pharmacological uses

Niacin, when taken in large doses, blocks the breakdown of fats in adipose tissue, thus altering blood lipid levels. Niacin is used in the treatment of hyperlipidemia because it reduces very-low-density lipoprotein (VLDL), a precursor of low-density lipoprotein (LDL) or "bad" cholesterol. Because niacin blocks breakdown of fats, it causes a decrease in free fatty acids in the blood and, as a consequence, decreased secretion of VLDL and cholesterol by the liver.[4]

By lowering VLDL levels, niacin also increases the level of high-density lipoprotein (HDL) or "good" cholesterol in blood, and therefore it is sometimes prescribed for patients with low HDL, who are also at high risk of a heart attack.[5][6] An extended release formulation of niacin for this indication is marketed by Abbott Laboratories under the trade name Niaspan.

Niacin is sometimes consumed in large quantities by people who wish to fool drug screening tests, particularly for lipid-soluble drugs such as marijuana.[7] It is believed to "promote metabolism" of the drug and cause it to be "flushed out." Scientific studies have shown it does not affect drug screenings, but can pose a risk of overdose, causing arrhythmias, metabolic acidosis, hyperglycemia, and other serious problems (see below).

In October 2008, Merck expanded the THRIVE Trial from 20,000 to 25,000 patients in order to expedite a second bid for FDA approval of its experimental cholesterol drug, MK-0524A. MK-0524A is a combination of niacin and laropiprant, which is aimed at limiting facial flushing associated with niacin. In April 2008 the FDA decided to withhold approval for the experimental drug, deciding to wait until the results of the THRIVE Trial could be analyzed.[8]

Toxicity

People taking pharmacological doses of niacin (1.5 - 6 g per day) often experience a syndrome of side-effects that can include one or more of the following:[9]

Facial flushing is the most commonly-reported side-effect.[10] It lasts for about 15 to 30 minutes, and is sometimes accompanied by a prickly or itching sensation. This effect is mediated by prostaglandins and can be blocked by taking 300 mg of aspirin half an hour before taking niacin, or by taking one tablet of ibuprofen per day. Taking the niacin with meals also helps reduce this side-effect. After 1 to 2 weeks of a stable dose, most patients no longer flush. Slow- or "sustained"-release forms of niacin have been developed to lessen these side-effects.[11][12] [13] One study showed the incidence of flushing was 4.5x lower (1.9 vs. 8.6 episodes in the first month) with a sustained-release formulation.[14]

Doses above 2 g per day have been associated with liver damage, particularly with slow-release formulations. [15]

High-dose niacin may also elevate blood sugar, thereby worsening diabetes mellitus.[16] Hyperuricemia is another side-effect of taking high-dose niacin; thus niacin may worsen gout.

Niacin at doses used in lowering cholesterol has been associated with birth defects in laboratory animals and should not be taken by pregnant women.[17]

Niacin at extremely high doses can have life-threatening acute toxic reactions. One patient suffered vomiting after taking eleven 500-milligram niacin tablets over 36 hours, and another was unresponsive for several minutes after taking five 500-milligram tablets over two days.[18][19] Extremely high doses of niacin can also cause niacin maculopathy, a thickening of the macula and retina which leads to blurred vision and blindness.[20]

Inositol hexanicotinate

One popular form of dietary supplement is inositol hexanicotinate, usually sold as "flush-free" or "no-flush" niacin (although those terms are also used for regular sustained-release.) While this form of niacin does not cause the flushing associated with the nicotinic acid form, it is not clear whether it is pharmacologically equivalent in its positive effect.[21]

Biosynthesis

The liver can synthesize niacin from the essential amino acid tryptophan (see below), but the synthesis is extremely inefficient; 60 mg of tryptophan are required to make one milligram of niacin.[22]

The 5-membered aromatic heterocycle of the essential amino acid, tryptophan, is cleaved and rearranged with the alpha amino group of tryptophan into the 6-membered aromatic heterocycle of niacin by the following reaction:

Biosynthesis: Tryptophankynurenine → niacin

Receptor

The receptor for niacin is a G-protein coupled receptor called HM74A.[23] It couples to Gi[24].

Food sources

Animal products: Fruits and vegetables: Seeds: Fungi:

References

  1. Northwestern University Nutrition
  2. 2.0 2.1 Vitamin B3 University of Maryland Medical Center.
  3. Template:Pauling
  4. T. Katzung, Basic and Clinical Pharmacology, 9th ed. p. 570.
  5. Postgraduate Medicine
  6. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-1255.
  7. Niacin abuse in the attempt to alter urine drug tests. Pharmacist's Letter/Prescriber's Letter 2007;23(6):230606.
  8. http://biz.yahoo.com/ap/081017/merck_cholesterol_study.html?.v=2
  9. J.G. Hardman et al., eds., Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th ed., p.991.
  10. NIH Medline Plus: Niacin. http://www.nlm.nih.gov/medlineplus/ency/article/002409.htm.
  11. J.G. Hardman et al., eds., Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th ed., p.991.
  12. T. Katzung, Basic and Clinical Pharmacology, 9th ed. p. 570.
  13. Options for therapeutic intervention: How effective are the different agents? European Heart Journal Supplements Vol 8 Suppl F Pp. F47-F53 [1]
  14. Chapman M, Assmann G, Fruchart J, Sheperd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Cur Med Res Opin. 2004 Aug;20(8):1253-68. PMID 15324528
  15. J.G. Hardman et al., eds., Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th ed., p.992.
  16. J.G. Hardman et al., eds., Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th ed., p.991.
  17. J.G. Hardman et al., eds., Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th ed., p.992.
  18. Hazards: Niacin to Pass a Drug Test Can Have Dangerous Results, By ERIC NAGOURNEY, New York Times, April 17, 2007[2]
  19. Mittal MK, Florin T, Perrone J, Delgado JH, Osterhoudt KC. Toxicity From the Use of Niacin to Beat Urine Drug Screening. Ann Emerg Med. 2007 Apr 4. PMID 17418450[3]
  20. JD Gass, Nictonic Acid Maculopathy, Am. J. Opthamology, 1973;76:500-10
  21. No-Flush Niacin for the Treatment of Hyperlipidemia
  22. Oxidization Reactions of Niacin from the Linus Pauling Institute at Oregon State University Linus Pauling Institute.
  23. medscape.com - The Metabolic Syndrome: Etiology, Controversies, and Emerging ...
  24. Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors Christian Zellner 1 *, Clive R. Pullinger 1, Bradley E. Aouizerat 2, Philip H. Frost 1, Pui-Yan Kwok 1, Mary J. Malloy 1, John P. Kane

External links

Template:Peripheral vasodilators Template:Lipid modifying agents